NEWS
3D CONSULTANTS WELCOME DR ROB PINNOCK TO THE PARTNERSHIP
April 2024
We are pleased to announce that Rob Pinnock has joined the Drug Discovery and Development (3D) Consultancy team.
Rob joins us from Biogen Idec where he was a director in external research, operating programmes in immunology, psychiatry, neurology and rare diseases. His background is in pharmacology and electrophysiology and Rob has more than 35 years drug discovery and development experience resulting in transitioning several programmes from concept through to clinical trials and marketed products. Rob has worked across both pharma and biotech having worked for Parke Davis, MSD, Pfizer, and is an author of over 70 peer reviewed publications.
Our consultancy partnership now benefits from a team of 14 scientists capable of providing expertise and guidance from early discovery through to and including PoC clinical studies. We will be further strengthening the 3D team through 2024 as we continue to broaden our skill sets and experience.
3D CONSULTANTS FURTHER EXPAND THEIR CMC CAPABILITY
November 2020
We would like to bring you up to date with some recent developments at 3D Consultants.
We are delighted to welcome Dr Mike Ashwood to the partnership. Mike joins us from a major UK-based biotech where he headed up the company’s CMC function. Consistent with 3D’s business model, our Directors have worked with Mike for many years and are fully aware of the considerable skill sets and experience that Mike brings to the team.
Over the last 6 months, the consultancy partnership has been able to grow its client base both in the US and UK despite the difficulties arising from the pandemic. These have included clients working on airway diseases including Covid-19 and mitochondrial-based disorders.
In addition to being able to welcome new business partners, the 3D Consultants team continue to work with our long term clients in the US, UK and Europe.
Our consultancy partnership benefits from a team of 15 scientists capable of providing expertise and guidance from early discovery through to clinical PoC and beyond. We will be looking to further strengthen the 3D Consultants team through 2020/21 and will keep you informed as our expertise and experience broadens.
We would be delighted to hear from you should you require any of our services. Please complete the form on our website with your query.
3D CONSULTANTS EXTEND THEIR CLIENT BASE TO THE US AND SUPPORT SUBMISSION TO THE FDA OF A NOVEL DRUG TARGETING COVID-19 SYMPTOMS
June 2020
We would like to bring you up to date with some recent developments at 3D Consultants.
Consistent with the consultancy partnership being recently strengthened through the addition of two US-based Associate Members, 3D Consultants now have long term contracts with three US clients.
One of our US clients is looking to initiate a Phase 2 trial to explore the effect of a novel drug with a compelling mechanism of action on key symptoms seen with severely ill patients suffering from Covid-19. 3D Consultants’ role has been to support submissions to the FDA.
3D Consultants has also been working with a US-based charitable foundation targeting the funding of novel drugs with the potential to alleviate neurodegenerative disorders.
In addition to these exciting new opportunities in the US, the 3D Consultants team continue to work with their long term clients both in the UK and Europe.
Our consultancy partnership benefits from a team of 14 scientists capable of providing expertise and guidance from early discovery through to clinical PoC and beyond. We will be looking to further strengthen the 3D Consultants team through 2020 and will keep you informed as our expertise and experience broadens.
We would be delighted to hear from you should you require any of our services. Please complete the form on our website with your query.
3D CONSULTANTS WELCOME BILL PULLMAN, PETE VAN ESS AND BRADLEY HARDIMAN TO THE TEAM
January 2020
We would like to bring you up to date with some recent developments at 3D Consultants as we move into the New Year.
US-based Drs Bill Pullman and Pete Van Ess bring a wealth of pre-clinical and clinical development experience to the team having worked across the entire development phase spectrum through to NDA and together make up our Translational Medicine capability. Both Bill and Pete have a broad appreciation of the regulatory approval process and Pete has a background in PK including PBPK simulation.
Bradley has an extensive background in commercialising research, specialising in early spin-out companies from Universities. Bradley also brings business development and licensing skills to the team.
Our consultancy partnership now benefits from a team of 14 scientists capable of providing expertise and guidance from early discovery through to clinical PoC but now also boasts a capability of being able to advise clients up to NDA. We will be looking to further strengthen the 3D team through 2020.
We would be delighted to hear from you should you require any of our services. Please complete the form on our website with your query.
3D CONSULTANTS WELCOME TIM SPAREY, ALLISON MORGAN, JOANNA SEGIETH AND SUE SNAPE TO THE TEAM
June 2019
We would like to bring you up to date with some recent developments at 3D Consultants as well as sharing with you some upcoming events.
Tim Sparey will be joining the 3D Consultants team to head up our Business Development activities. Tim is a serial entrepreneur with over 24 years of experience in large pharma and biotech companies with an extensive track record in corporate development, fundraising and business development.
We have recently increased the capability and capacity of our clinical development group with Allison Morgan, Joanna Segieth and Sue Snape joining the team. Sue, Joanna and Allison bring a wealth of experience to the team having worked across a variety of roles and disease areas in early clinical development phases.
Our consultancy partnership now benefits from a team of 13 scientists capable of providing expertise and guidance from early discovery through to and including PoC clinical studies. We will be looking to further strengthen the 3D team through 2019 and will keep you informed as our expertise and experience broadens.
3D Consultants are looking to out-license a GLP tox-ready D1 PAM programme which was divested following the acquisition of Proximagen
Please come and meet us at the Bio2Business event in Basle beginning on the 19th June and Bio Europe in Hamburg through 11-13th November.
Despite the company having been set up less than one year ago, we have already worked with a variety of companies and investors including long term ongoing contracts with BenevolentAI, Syndesi and Proximagen.
DR ISABEL GONZALEZ PRESENTS AS PART OF AN EDUCATIONAL COURSE ON TRANSLATING RESEARCH INTO DRUGS
June 2019
Please click here for the talk given by Dr Isabel Gonzalez as part of "An Educational Course on Translating Research into Drugs", at the 13th ANNUAL DRUG DISCOVERY FOR NEURODEGENERATION CONFERENCE (Presented by the Alzheimer’s Drug Discovery Foundation), March 17-19, 2019 (Long Beach, CA, USA). You can find all the other talks here.
3DCONSULTANTS STRENGTHENS RELATIONSHIP WITH BENEVOLENTAI
2018
Drug Discovery and Development Consultants Ltd have expanded the working relationship with BenevolentAI. Currently, three 3DC team members are working on BAI projects.
OBN MEMBERSHIP
2018
Drug Discovery and Development Consultants Ltd are now members of the OBN network. We will be attending OBN events in the near future. Find more information here.
3D CONSULTANTS DIRECTOR PRESENTS AT 16TH DRUG DISCOVERY FOR NEURODEGENERATION WORKSHOP
June 2022
The 16th Drug Discovery for Neurodegeneration Workshop was held online June 6-7, 2022. To find out more, follow this link.
The talk given by 3D Consultants director Isabel Gonzalez on the topic of "Efficacy, Target Engagement and Translatability of Preclinical Models of CNS Disease" is now available to watch, please follow this link.
Cummings, J.L., Gonzalez, M.I., Pritchard, M.C. et al.
The therapeutic landscape of tauopathies challenges and prospects.
Alz Res Therapy 15, 168 (2023).
THE 3D CONSULTANTS PARTNERSHIP IS PLEASED TO ANNOUNCE THE PUBLICATION
of a review of the landscape of tau protein therapeutics
October 2023
Dr Isabel Gonzalez and Dr Martyn Pritchard are co-authors of the publication, which was sponsored by the Rainwater Charitable Foundation.
Read it here.